RU94013464A - Нуклеозидные аналоги 1,3-оксатиолана, способ получения, фармацевтическая композиция, способ лечения вирусной инфекции - Google Patents
Нуклеозидные аналоги 1,3-оксатиолана, способ получения, фармацевтическая композиция, способ лечения вирусной инфекцииInfo
- Publication number
- RU94013464A RU94013464A RU94013464/04A RU94013464A RU94013464A RU 94013464 A RU94013464 A RU 94013464A RU 94013464/04 A RU94013464/04 A RU 94013464/04A RU 94013464 A RU94013464 A RU 94013464A RU 94013464 A RU94013464 A RU 94013464A
- Authority
- RU
- Russia
- Prior art keywords
- oxatiolane
- obtaining
- pharmaceutical composition
- nucleoside analogues
- viral infection
- Prior art date
Links
- 206010047461 Viral infection Diseases 0.000 title claims 2
- 208000001756 Virus Disease Diseases 0.000 title claims 2
- 239000002777 nucleoside Substances 0.000 title claims 2
- 239000008194 pharmaceutical composition Substances 0.000 title claims 2
- 230000017613 viral reproduction Effects 0.000 title claims 2
- 150000003833 nucleoside derivatives Chemical class 0.000 title 1
- XQSPYNMVSIKCOC-UHFFFAOYSA-N 4-amino-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one Chemical compound C1=C(F)C(N)=NC(=O)N1C1OC(CO)SC1 XQSPYNMVSIKCOC-UHFFFAOYSA-N 0.000 claims 1
- -1 nucleoside analogues of 1,3-oxathiolane Chemical class 0.000 claims 1
Claims (1)
- Изобретение относится к нуклеозидным аналогам 1,3-оксатиолана и их использованию при лечении вирусных инфекций. Более конкретно, изобретение относится к (-)-4-амино-5-фтор-1- (2-оксиметил-1,3-оксатиолан-5-ил) -(1Н)-пиримидин-2-ону и его фармацевтически приемлемым производным и содержащим их фармацевтическим составам.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9116601.7 | 1991-08-01 | ||
GB919116601A GB9116601D0 (en) | 1991-08-01 | 1991-08-01 | 1,3-oxathiolane nucleoside analogues |
PCT/CA1992/000321 WO1993003027A1 (en) | 1991-08-01 | 1992-07-24 | 1,3-oxathiolane nucleoside analogues |
Publications (2)
Publication Number | Publication Date |
---|---|
RU94013464A true RU94013464A (ru) | 1995-12-10 |
RU2126405C1 RU2126405C1 (ru) | 1999-02-20 |
Family
ID=10699340
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU94013464A RU2126405C1 (ru) | 1991-08-01 | 1992-07-24 | (-)-4-амино-5-фтор-1-(2-гидроксиметил-1,3-оксатиолан-5-ил)-(1h)-пиримидин- 2-он, смесь его энантиомеров, способы их получения, способ лечения |
Country Status (41)
Country | Link |
---|---|
US (2) | US5538975A (ru) |
EP (2) | EP0526253B1 (ru) |
JP (1) | JP2960778B2 (ru) |
KR (1) | KR100242454B1 (ru) |
CN (5) | CN101066970A (ru) |
AP (1) | AP321A (ru) |
AT (2) | ATE227720T1 (ru) |
AU (1) | AU659668B2 (ru) |
BG (1) | BG61693B1 (ru) |
CA (2) | CA2114221C (ru) |
CZ (1) | CZ283765B6 (ru) |
DE (2) | DE69232845T2 (ru) |
DK (2) | DK0526253T3 (ru) |
EE (1) | EE03002B1 (ru) |
EG (1) | EG20193A (ru) |
ES (2) | ES2186667T3 (ru) |
FI (1) | FI940435A0 (ru) |
GB (1) | GB9116601D0 (ru) |
GE (1) | GEP20002094B (ru) |
HK (2) | HK1008672A1 (ru) |
HN (1) | HN1997000118A (ru) |
HU (2) | HUT70030A (ru) |
IL (1) | IL102616A (ru) |
MA (1) | MA22919A1 (ru) |
MD (1) | MD1434C2 (ru) |
MX (1) | MX9204474A (ru) |
NO (3) | NO300842B1 (ru) |
NZ (1) | NZ243637A (ru) |
OA (1) | OA09883A (ru) |
PH (1) | PH30983A (ru) |
PT (2) | PT1155695E (ru) |
RS (1) | RS49993B (ru) |
RU (1) | RU2126405C1 (ru) |
SG (1) | SG68541A1 (ru) |
SK (1) | SK280131B6 (ru) |
TJ (1) | TJ244R3 (ru) |
TN (1) | TNSN92070A1 (ru) |
TW (2) | TWI232217B (ru) |
WO (1) | WO1993003027A1 (ru) |
YU (1) | YU49259B (ru) |
ZA (1) | ZA925668B (ru) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6903224B2 (en) | 1988-04-11 | 2005-06-07 | Biochem Pharma Inc. | Substituted 1,3-oxathiolanes |
US5276151A (en) * | 1990-02-01 | 1994-01-04 | Emory University | Method of synthesis of 1,3-dioxolane nucleosides |
US6703396B1 (en) | 1990-02-01 | 2004-03-09 | Emory University | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
US6642245B1 (en) | 1990-02-01 | 2003-11-04 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
US6069252A (en) * | 1990-02-01 | 2000-05-30 | Emory University | Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers |
US5204466A (en) * | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
US5925643A (en) * | 1990-12-05 | 1999-07-20 | Emory University | Enantiomerically pure β-D-dioxolane-nucleosides |
US5444063A (en) * | 1990-12-05 | 1995-08-22 | Emory University | Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity |
US6812233B1 (en) * | 1991-03-06 | 2004-11-02 | Emory University | Therapeutic nucleosides |
US5817667A (en) * | 1991-04-17 | 1998-10-06 | University Of Georgia Research Foudation | Compounds and methods for the treatment of cancer |
GB9116601D0 (en) * | 1991-08-01 | 1991-09-18 | Iaf Biochem Int | 1,3-oxathiolane nucleoside analogues |
GB9226927D0 (en) * | 1992-12-24 | 1993-02-17 | Iaf Biochem Int | Dideoxy nucleoside analogues |
GB9311709D0 (en) * | 1993-06-07 | 1993-07-21 | Iaf Biochem Int | Stereoselective synthesis of nucleoside analogues using bicycle intermediate |
US20020120130A1 (en) | 1993-09-10 | 2002-08-29 | Gilles Gosselin | 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents |
CA2171550C (en) * | 1993-09-10 | 2008-08-26 | Raymond F. Schinazi | Nucleosides with anti-hepatitis b virus activity |
US5587362A (en) * | 1994-01-28 | 1996-12-24 | Univ. Of Ga Research Foundation | L-nucleosides |
IL113432A (en) * | 1994-04-23 | 2000-11-21 | Glaxo Group Ltd | Process for the diastereoselective synthesis of nucleoside analogues |
IL115156A (en) | 1994-09-06 | 2000-07-16 | Univ Georgia | Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines |
US5703058A (en) * | 1995-01-27 | 1997-12-30 | Emory University | Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent |
US6391859B1 (en) | 1995-01-27 | 2002-05-21 | Emory University | [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides |
US5808040A (en) * | 1995-01-30 | 1998-09-15 | Yale University | L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides |
GB9506644D0 (en) * | 1995-03-31 | 1995-05-24 | Wellcome Found | Preparation of nucleoside analogues |
ES2276404T3 (es) | 1995-06-07 | 2007-06-16 | Emory University | Nucleosidos con actividad antivirus de la hepatitis-b. |
US5753789A (en) * | 1996-07-26 | 1998-05-19 | Yale University | Oligonucleotides containing L-nucleosides |
CN1196701C (zh) | 1997-03-19 | 2005-04-13 | 埃莫里大学 | 1,3-氧硒戊环核苷的合成及抗人类免疫缺陷病毒和抗乙肝病毒活性 |
JP2001518899A (ja) | 1997-04-07 | 2001-10-16 | トライアングル ファーマシューティカルズ,インコーポレイティド | 他の抗ウイルス剤との組合せにおけるmkc−442の使用 |
KR100856416B1 (ko) | 1998-08-12 | 2008-09-04 | 길리애드 사이언시즈, 인코포레이티드 | 1,3-옥사티올란 뉴클레오시드의 제조 방법 |
US6979561B1 (en) * | 1998-10-09 | 2005-12-27 | Gilead Sciences, Inc. | Non-homogeneous systems for the resolution of enantiomeric mixtures |
CN1666742A (zh) | 1998-11-02 | 2005-09-14 | 三角药物公司 | 对乙型肝炎病毒的联合治疗 |
US6436948B1 (en) | 2000-03-03 | 2002-08-20 | University Of Georgia Research Foundation Inc. | Method for the treatment of psoriasis and genital warts |
CA2405502A1 (en) * | 2000-03-29 | 2001-10-04 | Georgetown University | Method of treating hepatitis delta viral infection |
CA2308559C (en) | 2000-05-16 | 2005-07-26 | Brantford Chemicals Inc. | 1,3-oxathiolan-5-ones useful in the production of antiviral nucleoside analogues |
KR101015510B1 (ko) * | 2001-03-01 | 2011-02-16 | 길리애드 사이언시즈, 인코포레이티드 | 시스-ftc의 다형 및 기타 결정형 |
AU2008202336B2 (en) * | 2001-03-01 | 2011-11-10 | Abbvie Inc. | Polymorphic and other crystalline forms of cis-FTC |
WO2003051298A2 (en) * | 2001-12-14 | 2003-06-26 | Pharmasset Ltd. | Preparation of intermediates useful in the synthesis of antiviral nucleosides |
AU2004206821C1 (en) | 2003-01-14 | 2009-10-01 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
ITMI20030578A1 (it) | 2003-03-24 | 2004-09-25 | Clariant Lsm Italia Spa | Processo ed intermedi per la preparazione di emtricitabina |
TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
CN100360528C (zh) * | 2005-08-31 | 2008-01-09 | 四川大学 | 4-氨基-1-(2-羟甲基-1,3-氧硫杂环戊烷-5-基)-2(1h)-嘧啶酮的制备方法 |
WO2007077505A2 (en) * | 2005-12-30 | 2007-07-12 | Ranbaxy Laboratories Limited | Crystalline l-menthyl (2r, 5s)-5-(4-amino-5-fluoro-2-oxo-2h-pyrimidin-1-yl)[1, 3]oxathiolan-2-carboxylate and process for preparation thereof |
US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
AU2009329867B2 (en) | 2008-12-23 | 2015-01-29 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
TW201031675A (en) | 2008-12-23 | 2010-09-01 | Pharmasset Inc | Synthesis of purine nucleosides |
US8551973B2 (en) * | 2008-12-23 | 2013-10-08 | Gilead Pharmasset Llc | Nucleoside analogs |
RU2537264C2 (ru) * | 2009-04-03 | 2014-12-27 | Медикал Рисерч Каунсил | Мутанты индуцируемой активацией цитидиндеаминазы (aid) и способы их применения |
EP2377862A1 (en) | 2010-03-29 | 2011-10-19 | Esteve Química, S.A. | Process for obtaining emtricitabine |
HUE026235T2 (en) | 2010-03-31 | 2016-06-28 | Gilead Pharmasset Llc | Crystalline (S) -isopropyl 2 - (((S) - (((2R, 3R, 4R, 5R) -5- (2,4-dioxo-3,4-dihydropyrimidin-1 (2H) -IL) - 4-Fluoro-3-hydroxy-4-methyltetrahydrofuran-2-IL) methoxy) (phenoxy) phosphoryl) amino) propanoate |
JP5964454B2 (ja) | 2012-01-10 | 2016-08-03 | シシ イェンセン アクティー ゼルスカブC.C. Jensen A/S | 劣化油を浄化するための方法及びシステム |
US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5668674A (en) * | 1979-11-08 | 1981-06-09 | Shionogi & Co Ltd | 5-fluorouracil derivative |
DE2950317A1 (de) * | 1979-12-14 | 1981-06-19 | Agfa-Gevaert Ag, 5090 Leverkusen | Elektrothermographische vorrichtung |
US5466806A (en) * | 1989-02-08 | 1995-11-14 | Biochem Pharma Inc. | Processes for preparing substituted 1,3-oxathiolanes with antiviral properties |
US5047407A (en) * | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
US5270315A (en) * | 1988-04-11 | 1993-12-14 | Biochem Pharma Inc. | 4-(purinyl bases)-substituted-1,3-dioxlanes |
AU3154993A (en) * | 1989-02-08 | 1994-07-19 | Biochem Pharma Inc. | Process for preparing substituted 1,3-oxathiolanes with antiviral properties |
US5204466A (en) * | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
US5276151A (en) * | 1990-02-01 | 1994-01-04 | Emory University | Method of synthesis of 1,3-dioxolane nucleosides |
GB9009861D0 (en) * | 1990-05-02 | 1990-06-27 | Glaxo Group Ltd | Chemical compounds |
WO1992010496A1 (en) * | 1990-12-05 | 1992-06-25 | University Of Georgia Research Foundation, Inc. | ENANTIOMERICALLY PURE β-L-(-)-1,3-OXATHIOLANE NUCLEOSIDES |
US5248776A (en) * | 1990-12-05 | 1993-09-28 | University Of Georgia Research Foundation, Inc. | Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides |
US5444063A (en) * | 1990-12-05 | 1995-08-22 | Emory University | Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity |
IL100965A (en) * | 1991-02-22 | 1999-12-31 | Univ Emory | 2 - Hydroxymethyl - 5 -) 5 - Fluorocytocin - 1 - Eyal (- 1, 3 - Oxathiolane, its resolution and pharmaceuticals containing it |
KR100270806B1 (ko) * | 1991-03-06 | 2000-11-01 | 템블 존 엘 | 5-플루오로-2`-데옥시-3`-티아시티딘을 함유하는 b형 간염 치료를 위한 약제 |
GB9104740D0 (en) * | 1991-03-06 | 1991-04-17 | Wellcome Found | Antiviral nucleoside combination |
WO1992018517A1 (en) * | 1991-04-17 | 1992-10-29 | Yale University | Method of treating or preventing hepatitis b virus |
GB9111902D0 (en) * | 1991-06-03 | 1991-07-24 | Glaxo Group Ltd | Chemical compounds |
GB9116601D0 (en) * | 1991-08-01 | 1991-09-18 | Iaf Biochem Int | 1,3-oxathiolane nucleoside analogues |
-
1991
- 1991-08-01 GB GB919116601A patent/GB9116601D0/en active Pending
-
1992
- 1992-07-20 NZ NZ243637A patent/NZ243637A/en unknown
- 1992-07-23 IL IL10261692A patent/IL102616A/en not_active IP Right Cessation
- 1992-07-24 AU AU23408/92A patent/AU659668B2/en not_active Expired
- 1992-07-24 JP JP5503131A patent/JP2960778B2/ja not_active Expired - Lifetime
- 1992-07-24 CZ CZ94203A patent/CZ283765B6/cs not_active IP Right Cessation
- 1992-07-24 US US08/190,203 patent/US5538975A/en not_active Expired - Fee Related
- 1992-07-24 WO PCT/CA1992/000321 patent/WO1993003027A1/en active IP Right Grant
- 1992-07-24 CA CA002114221A patent/CA2114221C/en not_active Expired - Lifetime
- 1992-07-24 GE GEAP19922643A patent/GEP20002094B/en unknown
- 1992-07-24 CA CA2682254A patent/CA2682254C/en not_active Expired - Lifetime
- 1992-07-24 MD MD95-0114A patent/MD1434C2/ru unknown
- 1992-07-24 HU HU9400285A patent/HUT70030A/hu unknown
- 1992-07-24 KR KR1019940700260A patent/KR100242454B1/ko not_active IP Right Cessation
- 1992-07-24 SK SK104-94A patent/SK280131B6/sk not_active IP Right Cessation
- 1992-07-24 RU RU94013464A patent/RU2126405C1/ru active
- 1992-07-28 ZA ZA925668A patent/ZA925668B/xx unknown
- 1992-07-29 PH PH44737A patent/PH30983A/en unknown
- 1992-07-29 MA MA22897A patent/MA22919A1/fr unknown
- 1992-07-30 EG EG42992A patent/EG20193A/xx active
- 1992-07-31 YU YU74992A patent/YU49259B/sh unknown
- 1992-07-31 TW TW088109613A patent/TWI232217B/zh not_active IP Right Cessation
- 1992-07-31 TW TW081106093A patent/TW366347B/zh not_active IP Right Cessation
- 1992-07-31 TN TNTNSN92070A patent/TNSN92070A1/fr unknown
- 1992-07-31 MX MX9204474A patent/MX9204474A/es active IP Right Grant
- 1992-07-31 RS YUP-723/03A patent/RS49993B/sr unknown
- 1992-07-31 AP APAP/P/1992/000414A patent/AP321A/en active
- 1992-08-01 CN CNA2006100999088A patent/CN101066970A/zh active Pending
- 1992-08-01 CN CNA2006100999092A patent/CN101074228A/zh active Pending
- 1992-08-01 CN CN92108995A patent/CN1034810C/zh not_active Expired - Lifetime
- 1992-08-03 AT AT92307051T patent/ATE227720T1/de active
- 1992-08-03 DE DE69232845T patent/DE69232845T2/de not_active Expired - Lifetime
- 1992-08-03 EP EP92307051A patent/EP0526253B1/en not_active Expired - Lifetime
- 1992-08-03 DK DK92307051T patent/DK0526253T3/da active
- 1992-08-03 DE DE69233776T patent/DE69233776D1/de not_active Expired - Lifetime
- 1992-08-03 DK DK01119636.7T patent/DK1155695T3/da active
- 1992-08-03 EP EP01119636A patent/EP1155695B1/en not_active Expired - Lifetime
- 1992-08-03 SG SG1996001043A patent/SG68541A1/en unknown
- 1992-08-03 AT AT01119636T patent/ATE448787T1/de active
- 1992-08-03 ES ES92307051T patent/ES2186667T3/es not_active Expired - Lifetime
- 1992-08-03 PT PT01119636T patent/PT1155695E/pt unknown
- 1992-08-03 PT PT92307051T patent/PT526253E/pt unknown
- 1992-08-03 ES ES01119636T patent/ES2335968T3/es not_active Expired - Lifetime
-
1994
- 1994-01-28 FI FI940435A patent/FI940435A0/fi not_active Application Discontinuation
- 1994-01-31 NO NO940322A patent/NO300842B1/no not_active IP Right Cessation
- 1994-02-01 OA OA60465A patent/OA09883A/en unknown
- 1994-02-28 BG BG98616A patent/BG61693B1/bg unknown
- 1994-10-20 EE EE9400261A patent/EE03002B1/xx not_active IP Right Cessation
- 1994-12-15 TJ TJ94000128A patent/TJ244R3/xx unknown
-
1995
- 1995-06-07 US US08/487,452 patent/US5618820A/en not_active Expired - Fee Related
- 1995-06-30 HU HU95P/P00707P patent/HU211333A9/hu unknown
- 1995-11-03 CN CN95118741A patent/CN1074924C/zh not_active Expired - Lifetime
-
1997
- 1997-08-18 HN HN1997000118A patent/HN1997000118A/es unknown
-
1998
- 1998-07-02 HK HK98108820A patent/HK1008672A1/xx not_active IP Right Cessation
-
2000
- 2000-05-26 CN CNB001179012A patent/CN100542535C/zh not_active Expired - Lifetime
-
2001
- 2001-12-24 HK HK01109029.5A patent/HK1038189A1/xx not_active IP Right Cessation
-
2005
- 2005-08-19 NO NO2005017C patent/NO2005017I2/no not_active Application Discontinuation
-
2008
- 2008-06-12 NO NO2008009C patent/NO2008009I1/no unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU94013464A (ru) | Нуклеозидные аналоги 1,3-оксатиолана, способ получения, фармацевтическая композиция, способ лечения вирусной инфекции | |
TW366347B (en) | Antiviral pharmaceutical compositions comprising 1,3-oxathiolane nucleoside analogues | |
MY109796A (en) | 1,3-oxathiolane nucleoside analogues. | |
ATE219366T1 (de) | Verwendung von 5-fluoro-2'-deoxy-3'-thiacytidin zur behandlung von hepatitis b | |
UA29429C2 (ru) | Фармацевтическая композиция для лечения вирусных инфекций, способ получения композиции, способ лечения или профилактики вич-инфекции у человека | |
DE3689976D1 (de) | Therapeutische Nucleoside und deren Herstellung. | |
IL101836A0 (en) | Pharmaceutical compositions containing 1,3-oxathiolane nucleoside derivatives | |
RU93043875A (ru) | 1-(2-гидроксиметил)-1,3-оксатиолан-5-ил)-5-фторцитозин и способ лечения | |
HUP9801571A2 (hu) | Zidovudin, 1592U89 és 3TC vagy FTC szinergetikus kombinációi | |
MX9200747A (es) | Actividad antiviral y resolucion de 2-hidroximetilactividad antiviral y resolucion de 2-hidroximetil-5(5-fluorocitosin-1-il)-1,3-oxatiolano. -5(5-fluorocitosin-1-il)-1,3-oxatiolano. | |
WO2003051306A3 (en) | N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections | |
BR9808060A (pt) | Composição farmacêutica, processos para tratamento de infecções virais pela administração de uma quantidade farmaceuticamente segura e eficaz de uma composição farmacêutica, uso da lamivudina ou um seu derivado farmaceuticamente aceitável, e, processo para a preparação de uma composição farmacêutica. | |
BG100599A (en) | Antiviral form and therapeutical method | |
PT87004A (pt) | Process for the preparation of compositions for the treatment of viral infections and composites 3'-azide-2',3'-didesoxy-in osine and 3'-fluoro-2',3'-didesoxyguanosine | |
RU93058325A (ru) | Применение производных 1,3-оксатиолана для получения лекарственных препаратов для лечения или профилактики вирусной инфекции гепатита в, применение производных 1,3 - оксатиолана для лечения инфекций гепатита в, способ лечения гепатита в | |
WO2001030329A3 (en) | Combinations of lamivudine and entecavir for treatment of hepatitis b virus infuction | |
MY137298A (en) | Therapeutic nucleosides | |
MX9303985A (es) | Nucleosidos terapeuticos. | |
CA2140238A1 (en) | Antiviral combinations | |
MY113560A (en) | Use of 5-fluoro-2'-deoxy-3'-thiacytidine for the treatment of hepatitis b | |
RU93004467A (ru) | Замещенные пуриновые арабинозы, их применение, фармацевтическая композиция | |
WO2000016754A3 (en) | Antiviral combinations comprising lamivudine and lobucavir | |
IT1281501B1 (it) | Impiego di combinazioni di analoghi di nucleosidi nella terapia delle infezioni da virus dell'aids |